英国制药巨头葛兰素史克（GSK）今日盘前股价大幅上涨5.02%，引起了市场的广泛关注。
消息面上，该公司最新发布的第四季度财报显示，其利润超出市场预期，这主要得益于其艾滋病（HIV）药物以及一款用于治疗肺部疾病的哮喘药物的强劲表现。此外，公司给出了2026年利润增长7%至9%的积极指引，高于部分分析师此前预期的6%至8%，增强了投资者对公司未来业绩的信心。
新任首席执行官卢克·米尔斯（Luke Miels）设定了具有潜力的目标，其中抗癌药物Blenrep有望进一步提振公司收入。尽管公司面临部分药物专利到期等挑战，但其专科药物业务预计将实现低两位数增长，稳健的业绩表现和清晰的未来规划是推动股价在盘前交易时段走强的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.